This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
AboutAbout  CRESEMBA®Invasive fungal infections and risk factorsMeet CRESEMBA ®CRESEMBA® patient profilesEfficacyEfficacyInvasive AspergillosisMucormycosis

Menu

Close

LabelDosingDosingDosingSafety ProfileSafety & TolerabilitySafety ProfileEmerging PopulationsEmerging PopulationsICUInvasive fungal infections in the ICUInvasive fungal infections and influenza

Invasive fungal infections in solid organ transplant recipients

Invasive fungal infections and chronic obstructive pulmonary disease

Invasive fungal infections and COVID-19 (CAPA/CAM)Support & ResourcesResourcesKOL VideosNational/Regional GuidelinesECIL-6 Guidelines
ESCMID
ID Society of AmericaVideos
MaterialsSupport & Resources

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

Cresemba® (isavuconazole) - an antifungal triazole

For the treatment of invasive aspergillosis and also for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate1Learn more about invasive fungal infections

The incidence of invasive mould disease has increased in recent years2,3. These numbers show the estimated annual global cases of leading mould infections4. Find out more about mortality rates and risk factors for invasive mould disease. 

Learn moreLoading

Formulations and Stengths for Cresemba® 

Access all on demand videos and case studiesLoading Efficacy

Explore the study results for CRESEMBA® (isavuconazole) for the treatment of invasive aspergillosis with the SECURE study and mucormycosis in the VITAL study. 

 See the data - SECURE studyLoading See the data - VITAL studyLoading Safety

Read the details of the safety profile of Cresemba® (isavuconazole) including any contraindications, special warnings and precautions for use. 

Go to safety dataLoadingPatient Profiles

Get access to a number of example patient profiles for CRESEMBA® (isavuconazole)

View all patient profilesLoadingSee summary of profilesLoading Develop your antifungal stewardship

Discover resources designed to support you in adopting antifungal stewardship in your practice.

Find out moreLoading Downloadable materials

Download materials to help you treat your patients with CRESEMBA® (isavuconazole)

See all materialsLoading Dosing

Dosing recommendations for CRESEMBA® (isavuconazole)

 Access dosing information Loading Register for PfizerPro

Create an account to recieve tailored content specific to your interests

 Create a PfizerPro accountLoading

Click here for Prescribing Information for CRESEMBA (isavuconazole) and VFEND (voriconazole)

References:

CRESEMBA GB Summary of Product Characteristics.Binder U and Lass-Florl C. Mediterr J Hematol Infect Dis 2011;3(1):e20110016.2.Low CY and Rotstein C. F1000 Med Rep 2011;3:14.Bongomin F et al. J Fungi (Basel) 2017;3(4).
PP-CRB-GBR-1977. May 2023.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​